Achieve Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2020

Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

December 31, 2020	Level 1		Level 2		Level 3		Total
Assets
Cash	$	473	$	—	$	—	$	473
Money market securities (cash equivalents)		35,380		—		—		35,380
Restricted cash (Note 11)		50		—		—		50
Total assets	$	35,903	$	—	$	—	$	35,903

December 31, 2019	Level 1		Level 2		Level 3		Total
Assets
Cash	$	949	$	—	$	—	$	949
Money market securities (cash equivalents)		15,715		—		—		15,715
Restricted cash (Note 11)		50		—		—		50
Total assets	$	16,714	$	—	$	—	$	16,714

Summary of Cash and Cash Equivalents

Cash and cash equivalents (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
December 31, 2020	Cost		Gains		Losses		Fair Value
Cash	$	473	$	—	$	—	$	473
Money market securities		35,380		—		—		35,380
Total cash and cash equivalents	$	35,853	$	—	$	—	$	35,853
Money market securities (restricted cash)		50		—		—		50
Total restricted cash	$	50	$	—	$	—	$	50

			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
December 31, 2019	Cost		Gains		Losses		Fair Value
Cash	$	949	$	—	$	—	$	949
Money market securities		15,715		—		—		15,715
Total cash and cash equivalents	$	16,664	$	—	$	—	$	16,664
Money market securities (restricted cash)		50		—		—		50
Total restricted cash	$	50	$	—	$	—	$	50